Brief: Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program After Strong Positive Phase 2 Results

Pfizer

20/05/2026 10:05

May 20 (Reuters) - Pfizer Inc PFE.N:

PFIZER: ADVANCES PIVOTAL PEDIATRIC PNEUMOCOCCAL VACCINE PROGRAM FOLLOWING STRONG POSITIVE PHASE 2 RESULTS

PFIZER: 25VPNC PHASE 2 DATA SHOWS ROBUST IMMUNOGENICITY, INCLUDING ENHANCED RESPONSE AGAINST SEROTYPE 3, WITH EXPANDED PROTECTION ACROSS 25 SEROTYPES

PFIZER: 25VPNC WELL-TOLERATED WITH NO SAFETY CONCERNS IDENTIFIED IN PHASE 2 STUDY

PFIZER: INITIATED ITS PHASE 3 25VPNC PEDIATRIC PROGRAM

PFIZER: ABOUT 9 TO 15-FOLD HIGHER SEROTYPE 3 IMMUNOGENICITY RESPONSE AFTER DOSE 3 & 4 IN INFANTS RECEIVING 25VPNC VERSUS  PREVNAR 20

PFIZER: 25VPNC EXPECTED TO COVER UP TO 90% OF DISEASE-CAUSING SEROTYPES IN CHILDREN UNDER AGE OF 5, INCLUDING ABOUT 15% FROM SEROTYPE 3

PFIZER: ADULT PNEUMOCOCCAL VACCINE CANDIDATE EXPECTED TO ENTER CLINICAL DEVELOPMENT BY END OF 2026

Further company coverage: PFE.N

 ((Reuters.Briefs@thomsonreuters.com;))